Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Editas Medicine (NQ: EDIT )

7.009 -0.101 (-1.42%)
Streaming Delayed Price Updated: 2:17 PM EDT, Sep 26, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine

< Previous 1 2 3 4 5 6 7 8 9 Next >
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Why Brainstorm Cell Therapeutics Shares Are Trading Lower By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares jumped 308% to $2.71 after the company announced pre-clinical gliblastoma results with its lead candidate, TTX-MC138. 
Via Benzinga
Analyst Expectations for Editas Medicine's Future
Via Benzinga
Expert Ratings for Editas Medicine
Via Benzinga
Is Editas Medicine Stock a Buy Now?
The fortunes of this once-promising biotech company have changed in the past year. 
Via The Motley Fool
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Gene Editing Stock to Buy Now, and 1 to Sell
Target markets matter. So does having the cash to get to them. 
Via The Motley Fool
Editas Medicine Announces Upcoming Investor Events
From Editas Medicine, Inc.
Via GlobeNewswire
What 6 Analyst Ratings Have To Say About Editas Medicine
Via Benzinga
These 2 Stocks Could Skyrocket by 54% and 119%, According to Wall Street
Is the Street's optimism justified here? 
Via The Motley Fool
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
From Editas Medicine, Inc.
Via GlobeNewswire
This 1 Problem Could Sink at Least 4 Gene-Editing Stocks
Reaching profitability could be harder than investors expect. 
Via The Motley Fool
What Is CRISPR And Why Should Your Portfolio Care?
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player. 
Via Talk Markets
After It Fell 15% in 1 Day, Should You Buy The Dip on Editas Stock?
It's not about to start making money anytime soon. 
Via The Motley Fool
Why John Wiley & Sons Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers SCWorx Corp. (NASDAQ: WORX) shares jumped 281% to $0.8396. 
Via Benzinga
2 Short-Squeeze Candidates That Could Go Parabolic
Editas Medicine and Bluebird Bio have been favorite targets for short-sellers lately. 
Via The Motley Fool
Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Editas Medicine Announces Pricing of Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Editas Medicine Announces Offering of Common Stock
From Editas Medicine, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 13, 2023
Via Benzinga
5 Stocks to Buy With Explosive 500% Potential
Take advantage of a bullish change in investor sentiment with these five stocks to buy for 500% upside potential. 
Via InvestorPlace
Editas' Gene Editing Treatment Shows Initial Safety, Efficacy In Patients With Rare Blood Disorders
Editas Medicine Inc (NASDAQ: EDIT) annou 
Via Benzinga
Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial
From Editas Medicine, Inc.
Via GlobeNewswire
Why Are Gene Editing Stocks EDIT, NVTA, CRSP Up Today?
Gene editing stocks are up today on news that Editas Medicine will present clinical data on June 12. Here's what this means for the sector. 
Via InvestorPlace
Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia
From Editas Medicine, Inc.
Via GlobeNewswire
Genprex (NASDAQ: GNPX) Releases New Patient Video Interview Describing Positive Experience in Clinical Trial
A clinical-stage gene therapy company is making splashes in the medical world. Genprex, Inc. (NASDAQ: GNPX) is developing potentially life-changing therapies for patients with cancer and diabetes that... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.